New optically pumped magnetometers (OPM) coming to Oxford
The Oxford Centre for Human Brain Activity, led by Prof. Mark Woolrich, has been granted a cutting-edge piece of neuroimaging equipment – the Optically Pumped Magnetometers (OPMs).
AI to help personalise treatment for depression as part of major trial
People with depression are being invited to be part of a clinical trial testing a new evidence-based AI treatment tool to personalise antidepressant treatment.
Professor Mina Fazel appointed Chair of Child and Adolescent Psychiatry
She will lead the Child and Adolescent Psychiatry research group, aiming to better understand how to prevent mental health difficulties in children and young people and how best to support them and their families.
Trial including Oxford will test if drug can reduce depression following brain injury
Up to 50 per cent of people who suffer a traumatic brain injury (TBI) go on to develop some form of depression in the 10 years following the injury.
Blood tests for diagnosing dementia a step closer
The University of Oxford and Oxford Health Clinical Research Facility is part of country-wide trials to identify accurate and quick blood tests that can diagnose dementia.
What is Patient and Public Involvement?
Everyone benefits from research. Research provides evidence about what works best. Patients, carers, people who use social care services and health & social care professionals all use this evidence to make decisions about treatments and care.
Reflections on conducting inclusive, participatory research in NHS settings
Dr Roisin Mooney, Project Manager and Postdoctoral Researchers in the CHiMES Collaborative and Co-Principal Investigator of the Co-Pact study, outlines her thoughts on important considerations for inclusive research, based on her experience.
Professor Rachel Upthegrove appointed Director Designate of the Oxford Health BRC
We are delighted to announce that Professor Rachel Upthegrove has been appointed as the new director designate and Senior Clinical Researcher of the Oxford Health Biomedical Research Centre (OH BRC) based at the University of Oxford’s Department of Psychiatry. She will officially start in August 2024, succeeding Professor John Geddes, who has led the BRC since 2017 and will step down by the end 2024.
Access to dementia research trials to be extended across the UK
The announcement comes as the government announces nearly £50 million of new funding.
Recruitment for Alzheimer’s Disease study now open at Oxford Health Clinical Research Facility (OH CRF)
Alzheimer’s Disease is a type of dementia in which abnormal proteins, called beta-amyloid and tau, accumulate in the brain and damage nerve cells. People with Alzheimer’s Disease often have trouble thinking, speaking, remembering things, and performing their daily activities. This condition is common in older people and gets worse over time.